Industry

Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress

35 Percent of Patients Treated With CTP-543 12 mg Twice-Daily Achieved At Least 90 Percent Scalp Hair Coverage (SALT Score ≤ 10) After 24 Weeks of Treatment Newly-Reported Results Show Significant Improvement in Eyebrow and Eyelash Regrowth in Patients Treated With Both Doses of CTP-543 MILAN–(BUSINESS WIRE)–$CNCE #AlopeciaAreata—Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the … [Read more…]

DS-7300 Continues to Show Promising Durable Response in Patients with Several Types of Advanced Cancer

Extended follow-up data from phase 1/2 trial of DS-7300 in patients with metastatic lung, prostate or esophageal cancer to be featured in Proffered Paper session at ESMO TOKYO, BASKING RIDGE, N.J. & NASHVILLE, Tenn.–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) and Sarah Cannon Research Institute (SCRI) announced that extended follow-up data from a phase 1/2 trial of … [Read more…]

Wugen Presents Preclinical Data on WU-NK-101 in Solid Tumor Models at the European Society for Medical Oncology (ESMO) Congress 2022

— WU-NK-101 exhibited enhanced metabolic fitness and adaptability, enabling superior resilience within the immunosuppressive solid tumor microenvironment and preserved cytotoxic function — — WU-NK-101 demonstrated robust anti-tumor activity, tumor trafficking, and penetration further augmented by monoclonal antibodies (mAbs) — — Data support the clinical development of WU-NK-101 for solid tumor indications — ST. LOUIS & … [Read more…]

Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022

– Both single-agent XL092 and XL092 in combination with atezolizumab demonstrated encouraging efficacy and safety in a heavily pretreated patient population – – XL092 demonstrated preliminary clinical activity similar to that observed with cabozantinib in phase 1 across a range of solid tumors and dose levels, with a manageable safety profile – – Based on … [Read more…]

Bristol Myers Squibb Announces New Sotyktu™ (deucravacitinib) Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis

Results add to the growing body of evidence and reinforce the efficacy profile of Sotyktu, a once-daily, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasis New analysis to be presented at the 2022 European Academy of Dermatology and Venereology Congress as part of 26 company-sponsored scientific presentations, demonstrating … [Read more…]

Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022 RAHWAY, N.J. & NUTLEY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced the first presentation of results from the final analysis of the Phase 3 LEAP-002 … [Read more…]

BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer

Tislelizumab demonstrated non-inferiority for overall survival and favorable safety profile versus sorafenib in global Phase 3 trial Additional poster presentations show breadth of tislelizumab global clinical development program as single-agent treatment and in combination CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on … [Read more…]

  U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis

  Bristol Myers Squibb’s Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 years Pivotal Phase 3 POETYK PSO clinical trials demonstrated superior efficacy of once-daily Sotyktu over placebo and twice-daily Otezla® (apremilast) … [Read more…]

Antibe Announces Results of 2022 Annual Meeting

TORONTO–(BUSINESS WIRE)–$ATBPF–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today. All resolutions outlined in the management information circular were approved. Detailed results for the … [Read more…]

Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner

Next-generation assay combines 800+-gene panel with exome-wide methylation detection to provide novel genomic and epigenomic insights into tumor, tumor microenvironment and patient immune responses from a simple blood draw Researchers can access additional modular content to gain insight into and direct patient selection for IO, HRD and other targeted therapies with no need for additional … [Read more…]